Position Papers

July 15, 2020

COVID-19 and Thalassaemia

This position statement examines the heightened risks COVID-19 may pose to people with thalassaemia and sickle cell disease, alongside adaptations to care, transfusion safety and blood supply challenges.
Read More »
July 10, 2020

The Use of DEHP Plasticizers in Medical Devices

TIF’s statement examines safety concerns surrounding DEHP, a plasticiser used in blood bags and PVC intravenous sets. It follows the European Commission’s SCHEER guidelines (June 2019) and the subsequent decision…
Read More »
April 22, 2020

COVID-19: Recognising People with Thalassaemia and Sickle Cell Disease as a High-Risk Group

In this position statement, TIF calls on national health authorities worldwide to adopt policies that safeguard the health and lives of people with haemoglobin disorders during the COVID-19 pandemic.
Read More »
August 13, 2018

TIF’s Positions in a Nutshell

This document brings together TIF’s positions on key issues affecting people with thalassaemia and other haemoglobin disorders, providing a practical reference for patient advocates, healthcare professionals and policymakers to support…
Read More »
December 22, 2017

Safeguarding Blood Safety

TIF’s ‘Safeguarding Blood Safety’ position paper complements its educational work on this vital aspect of thalassaemia care. It forms part of a series addressing issues central to effective disease management…
Read More »
August 4, 2017

Viral Hepatitis C in Thalassaemia

In 2014, the Thalassaemia International Federation (TIF) took action to highlight the need for access to antiviral treatment for people with thalassaemia living with hepatitis C.
Read More »
August 4, 2017

Patients’ Rights

Providing patients and their families with reliable, up-to-date information is a core responsibility of patient organisations, particularly those supporting people with lifelong genetic conditions such as thalassaemia.
Read More »
August 4, 2017

Counterfeit Medicines and Patients’ Safety

The Thalassaemia International Federation (TIF) continues to advocate for stronger, more coordinated action to protect patients from counterfeit medicines.
Read More »
August 4, 2017

Addressing the Management of NTDTs

This position paper highlights the need for early, proactive care for people with non-transfusion-dependent thalassaemias (NTDT). It emphasises appropriate transfusion support and the monitoring and treatment of iron overload to…
Read More »